Welcome to Scribd, the world's digital library. Read, publish, and share books and documents. See more
Download
Standard view
Full view
of .
Save to My Library
Look up keyword
Like this
9Activity
0 of .
Results for:
No results containing your search query
P. 1
Hemodialysis Article

Hemodialysis Article

Ratings: (0)|Views: 134 |Likes:
Published by boiean

More info:

Published by: boiean on Jan 08, 2010
Copyright:Attribution Non-commercial

Availability:

Read on Scribd mobile: iPhone, iPad and Android.
download as DOC, PDF, TXT or read online from Scribd
See more
See less

05/22/2012

pdf

text

original

 
Interferon is effective in hemodialysis patients withhepatitis C
by Michelle Rizzo
Last Updated: 2009-02-29 15:57:06 -0400 (Reuters Health)
NEW YORK (Reuters Health) - A paper in the February issue of the American Journalof Kidney Diseases suggests that in hemodialysis patients with hepatitis C virus (HCV)infection, interferon (IFN) therapy achieves good rates of sustained virological response.Dr. Craig E. Gordon and colleagues at Tufts-New England Medical Center in Bostonconducted a meta-analysis and meta-regression of randomized controlled trials,uncontrolled trials, and prospective observational studies in order to assess the risksand benefits of using IFN and pegylated IFN (PEG-IFN), with and without ribavirin, totreat hemodialysis patients who have chronic HCV infection. To be included, studieshad to report on virological response at least 5 months after treatment.The studies included 20 in which a total of 459 patients were given IFN, 3 in which 38patients were treated with PEG-IFN, and 2 in which 49 patients received PEG-IFN andribavirin.Overall in the 25 studies, the sustained viral response to IFN was 41%. For PEG-IFN,the overall sustained viral response was 37%. The authors report that viral responserates were higher when the dose of IFN was at least 3 million units. Sustained viralresponse was also higher with lower mean HCV RNA levels and with lower rates of cirrhosis, HCV genotype 1 or elevated transaminase, but not to a statistically significantdegree.Frequently reported adverse events included influenza-like illness, anemia, symptomaticrejection of a nonfunctioning kidney graft, depression, leukopenia, confusion, diarrhea,thrombocytopenia, and seizures. Combined treatment discontinuation rates were 26%for IFN and 28% for PEG-IFN."The sustained virological response of 41% to interferon in dialysis patients is nearly ashigh as that seen with pegylated-interferon and ribavirin combination therapy in thegeneral population of patients who are not on dialysis," Dr. Gordon said in an interviewwith Reuters Health. "This is important because dialysis patients cannot receive ribavirinbecause of a high rate of side effects," he explained. "We think the higher response tointerferon is because of fixed dosage in patients with impaired kidney function resultingin higher drug levels leading to greater efficacy but also a higher rate of side effects,although this is not yet proven.""Most physicians would expect that the treatment of hepatitis C virus would be lesssuccessful in hemodialysis patients," Dr. Gordon said. "We found the opposite, and in
 
fact the treatment was more successful in hemodialysis patients, suggesting thatperhaps more patients should be considered for treatment."The author noted that there is a high risk of side effects from interferon, so patientsneed to be selected carefully. "For instance, hemodialysis patients with untreateddepression would not be good candidates for treatment because interferon can worsendepression," he said. "So there are several reasons to be cautious with treatment," headded.Am J Kidney Dis 2008;51:263-277.Copyright Reuters 2009.

You're Reading a Free Preview

Download
/*********** DO NOT ALTER ANYTHING BELOW THIS LINE ! ************/ var s_code=s.t();if(s_code)document.write(s_code)//-->